Skip to Content

Phytonadione Tablets

Dosage Form: tablet

Medically reviewed on May 1, 2018

Phytonadione Tablets Description

Phytonadione is a vitamin which is a clear, yellow to amber, viscous, and nearly odorless liquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.70.

Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is C31H46O2 and its structural formula is:

Phytonadione Tablets, USP containing 5 mg of phytonadione, USP, is light yellow to yellow colored, round tablets.

Inactive Ingredients

Phytonadione Tablets USP, 5 mg contains: acacia, anhydrous dibasic calcium phosphate, colloidal silicon dioxide, lactose monohydrate, magnesium stearate, pregelatinized starch and talc.

Phytonadione Tablets - Clinical Pharmacology

Phytonadione possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors - II, VII, and X. Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post-translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxyglutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function; that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors.

Phytonadione Tablets generally exert their effect within 6 to 10 hours.

Indications and Usage for Phytonadione Tablets

Phytonadione Tablets are indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

Phytonadione Tablets are indicated in:

— anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives;

— hypoprothrombinemia secondary to antibacterial therapy;

— hypoprothrombinemia secondary to administration of salicylates;

— hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed.

Contraindications

 Hypersensitivity to any component of this medication.

Warnings

An immediate coagulant effect should not be expected after administration of phytonadione.

Phytonadione will not counteract the anticoagulant action of heparin.

When vitamin K1 is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly as clinical conditions indicate.

Repeated large doses of vitamin K are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory. Failure to respond to vitamin K may indicate a congenital coagulation defect or that the condition being treated is unresponsive to vitamin K.

Precautions

General

 Vitamin K1 is fairly rapidly degraded by light; therefore, always protect phytonadione from light. Store phytonadione in closed original carton until contents have been used (see also HOW SUPPLIED, Storage).

Drug Interactions

 Temporary resistance to prothrombin-depressing anticoagulants may result, especially when larger doses of phytonadione are used. If relatively large doses have been employed, it may be necessary when reinstituting anticoagulant therapy to use somewhat larger doses of the prothrombin-depressing anticoagulant, or to use one which acts on a different principle, such as heparin sodium.

Laboratory Tests

 Prothrombin time should be checked regularly as clinical conditions indicate.

Carcinogenesis, Mutagenesis, Impairment of Fertility

 Studies of carcinogenicity or impairment of fertility have not been performed with phytonadione. Phytonadione at concentrations up to 2,000 mcg/plate with or without metabolic activation, was negative in the Ames microbial mutagen test.

Pregnancy

 Pregnancy Category C: Animal reproduction studies have not been conducted with phytonadione. It is also not known whether phytonadione can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phytonadione should be given to a pregnant woman only if clearly needed.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established with phytonadione. Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, have been reported with vitamin K. 

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when phytonadione is administered to a nursing woman. 

Geriatric Use

Clinical studies of phytonadione did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 

Adverse Reactions

Severe hypersensitivity reactions, including anaphylactoid reactions and deaths have been reported following parenteral administration. The majority of these reported events occurred following intravenous administration.

Transient “flushing sensations” and “peculiar” sensations of taste have been observed with parenteral phytonadione, as well as rare instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis.

Hyperbilirubinemia has been observed in the newborn following administration of parenteral phytonadione. This has occurred rarely and primarily with doses above those recommended.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Overdosage

The intravenous and oral LD50s in the mouse are approximately 1.17 g/kg and greater than 24.18 g/kg, respectively. 

Phytonadione Tablets Dosage and Administration

Phytonadione Tablets
Summary of Dosage Guidelines
(See circular text for details)

Adults

Initial Dosage

Anticoagulant-Induced
Prothrombin Deficiency

(caused by coumarin or indanedione derivatives)

2.5 mg to 10 mg or up to

25 mg (rarely 50 mg)

Hypoprothrombinemia due
to other causes

(Antibiotics; Salicylates or other drugs;
Factors limiting absorption or synthesis)

2.5 mg to 25 mg or more

(rarely up to 50 mg)


Anticoagulant-Induced Prothrombin Deficiency in Adults

To correct excessively prolonged prothrombin times caused by oral anticoagulant therapy - 2.5 to 10 mg or up to 25 mg initially is recommended. In rare instances 50 mg may be required. Frequency and amount of subsequent doses should be determined by prothrombin time response or clinical condition (see WARNINGS). If, in 12 to 48 hours after oral administration, the prothrombin time has not been shortened satisfactorily, the dose should be repeated.

Hypoprothrombinemia Due to Other Causes in Adults

If possible, discontinuation or reduction of the dosage of drugs interfering with coagulation mechanisms (such as salicylates, antibiotics) is suggested as an alternative to administering concurrent Phytonadione Tablets. The severity of the coagulation disorder should determine whether the immediate administration of Phytonadione Tablets is required in addition to discontinuation or reduction of interfering drugs.

A dosage of 2.5 to 25 mg or more (rarely up to 50 mg) is recommended, the amount and route of administration depending upon the severity of the condition and response obtained.

The oral route should be avoided when the clinical disorder would prevent proper absorption. Bile salts must be given with the tablets when the endogenous supply of bile to the gastrointestinal tract is deficient.

How is Phytonadione Tablets Supplied

Phytonadione Tablets USP, 5 mg are supplied as light yellow to yellow colored, round, scored tablets, debossed with “AA” and “05” on either side of scoring and plain on the other side.
They are available as follows:

Bottle of 30 Tablets:                          NDC 69238-1051-3
Bottle of 100 Tablets:                        NDC 69238-1051-1

Storage:

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Always protect Phytonadione Tablets, USP from light. Store in tightly closed original container and carton until contents have been used (see PRECAUTIONS, General).

Manufactured by:
Amneal Pharmaceuticals Pvt. Ltd.
Oral Solid Dosage Unit

Ahmedabad 382213, INDIA

Distributed by:
Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

Rev. 10-2017-00

PRINCIPAL DISPLAY PANEL

NDC 69238-1051-3

Phytonadione Tablets USP, 5 mg

Rx Only

30 Tablets

Amneal Pharmaceuticals LLC

PHYTONADIONE 
phytonadione tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:69238-1051
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PHYTONADIONE (PHYTONADIONE) PHYTONADIONE 5 mg
Inactive Ingredients
Ingredient Name Strength
ACACIA ANGUSTISSIMA BARK  
ANHYDROUS DIBASIC CALCIUM PHOSPHATE  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
SILICON DIOXIDE  
STARCH, PREGELATINIZED CORN  
TALC  
Product Characteristics
Color YELLOW (Light yellow to yellow) Score 2 pieces
Shape ROUND Size 6mm
Flavor Imprint Code AA;05
Contains     
Packaging
# Item Code Package Description
1 NDC:69238-1051-3 1 BOTTLE in 1 CARTON
1 30 TABLET in 1 BOTTLE
2 NDC:69238-1051-1 1 BOTTLE in 1 CARTON
2 100 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA209373 05/15/2018
Labeler - Amneal Pharmaceuticals LLC (123797875)
Establishment
Name Address ID/FEI Operations
Amneal Pharmaceuticals Private Limited Oral Solid Dosage Unit 650762060 MANUFACTURE(69238-1051), PACK(69238-1051)
 
Amneal Pharmaceuticals LLC
Hide